Data supporting figures, tables and supplementary information in the published article: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou
Yan Liu
Xiaobo Lei
Pei Li
Dan Mi
Lili Ren
Li Guo
Ruixuan Guo
Ting Chen
Jiaxin Hu
Zichun Xiang
Zhixia Mu
Xing Chen
Jieyong Chen
Keping Hu
Qi Jin
Jianwei Wang
Zhaohui Qian
10.6084/m9.figshare.11954889.v1
https://springernature.figshare.com/articles/dataset/Data_supporting_figures_tables_and_supplementary_information_in_the_published_article_Characterization_of_spike_glycoprotein_of_SARS-CoV-2_on_virus_entry_and_its_immune_cross-reactivity_with_SARS-CoV/11954889
This dataset comprises a single Excel .xlsx spreadsheet with 29 tabs. The data are western blot images and quantitative data characterising spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. The data underlie the figures, table and supplementary figures of the related manuscript.<div><br></div><div>The 29 tabs are as follows. (NOTE: Western blot images do not display in figshare viewer: please download the spreadsheet to view these)<div><div>- Western blots for incorporation of SARS-CoV-2 S protein into pseudovirions.</div><div>(<b>Figure 1B, </b><b>Figure 1C, </b><b>Figure 1D, </b><b>Figure 1E, </b><b>Figure 1F</b>, <b>Figure 1G, </b><b>Figure 1H, </b><b>Figure 1I, </b><b>Figure 1J</b>)</div><div>- Entry and receptor of SARS-CoV-2 S pseudovirons.</div><div>(<b>Figure 2A, </b><b>Figure 2B, Figure 2D</b>)</div><div>- Endocytosis of SARS-CoV-2 S pseudovirions on 293/hACE2 cells.</div><div>(<b>Figure 3A, </b><b>Figure 3B</b><b>, </b><b>Figure 3C</b><b>, </b><b>Figure 3D</b><b>, </b><b>Figure 3E</b><b>, </b><b>Figure 3F</b>)</div><div>- Activation of SARS-CoV-2 S protein by cathepsin and trypsin.</div><div>(<b>Figure 4A, </b><b>Figure 4C, </b><b>Figure 4D, </b><b>Figure 4E</b>)</div><div>- Characterization of polyclonal rabbit anti-SARS S1 antibodies T62.</div><div>(<b>Figure 5B, Figure 5E</b>)</div><div>- Limited cross-neutralization of SARS-CoV and COVID-19 sera.</div><div>(<b>Figure 6A, </b><b>Figure 6B</b>)</div><div>- Neutralization activities of antisera from SARS-CoV and COVID-19 patients.</div><div>(<b>Table 1</b>)</div><div>- Treatment of cells with 130, a TRPML1 inhibitor.</div><div>(<b>Supplementary Figure 1</b>)</div><div>- Expressing type II membrane serine protease (TMPRSS) 2, 4, 11A, 11D, and 11E on 293/hACE2 cells.</div><div>(<b>Supplementary Figure 3</b>).</div><div><b><br></b></div><div>In the related publication, the authors use a lentiviral pseudotype system and determine cell type susceptibility, virus receptor, entry pathway and protease priming for SARS-CoV-2. They also identify several potential drug targets for SARS-CoV-2.</div><div><br></div></div></div>
2020-03-26 17:40:24
SARS-CoV-2
virus entry
immune cross-reactivity
SARS-CoV
spike glycoprotein
beta coronavirus
CoV
MERS-CoV
hACE2
human angiotensin converting enzyme 2
2019-nCoV
COVID-19
coronavirus